Evaluating the Impact of COVID-19 on Clinical Decision Making During the Initial Outbreak in a High-prevalence Environment

por Pendyala, P., Abou Yehia, Z., Grann, A., Wagman, R.T., Huang, D., Ennis, R.D.
Publicado 2020

Observations following discontinuation of long-term denosumab therapy

por McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., Lewiecki, E. M.
Publicado 2017

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

por McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.
Publicado 2012

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

por Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, C., Wagman, R. B., Cummings, S. R.
Publicado 2016

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

por Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., O’Malley, C. D., Wagman, R. B., Libanati, C., Lewiecki, E. M.
Publicado 2015

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

por Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.
Publicado 2015